Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000620 · ClinicalTrials.gov registry record · Phase 3
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
A Phase 3 study of Hypertension and Diabetes Mellitus, Type 2, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 10,251
- Enrollment target
- 7
- Study locations
NCT00000620 is a Phase 3 study of Hypertension and Diabetes Mellitus, Type 2 that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 10,251 participants, above the 3,486-participant average among 470 other Hypertension trials with a reported enrollment target (194% higher). The trial reports 7 study locations across 7 states.
The verdict
NCT00000620, a Phase 3 study of Hypertension and Diabetes Mellitus, Type 2, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,251 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Conditions Studied
Interventions
- DRUG Anti-hyperglycemic Agents
- DRUG Anti-hypertensive Agents
- DRUG Blinded fenofibrate or placebo plus simvastatin
Study Locations (7)
Minnesota
- Minneapolis Medical Research Foundation - Minneapolis
New York
- Columbia University - New York
North Carolina
- Wake Forest University - Winston-Salem
Ohio
- Case Western Reserve University - Cleveland
Tennessee
- Veterans Affairs - Memphis
Washington
- University of Washington - Seattle
Ontario
- McMaster University - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,251 participants |
| Start Date | 1999-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000620
The ClinicalTrials.gov registry entry for NCT00000620 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10,251 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,486-participant average among 470 other Hypertension trials with a reported enrollment target (194% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Anti-hyperglycemic Agents is the first listed.
NCT00000620 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Minnesota, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00000620 about?
NCT00000620 is a clinical study titled "Action to Control Cardiovascular Risk in Diabetes (ACCORD)". The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
What is the current status of trial NCT00000620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,251 participants. The study started on 1999-09. Estimated completion is 2012-12.
What conditions does trial NCT00000620 study?
This clinical trial studies the following conditions: Hypertension, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetes Mellitus, Atherosclerosis.
What interventions are being tested in trial NCT00000620?
The interventions under investigation include: Anti-hyperglycemic Agents (DRUG), Anti-hypertensive Agents (DRUG), Blinded fenofibrate or placebo plus simvastatin (DRUG).
Who is sponsoring clinical trial NCT00000620?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000620 being conducted?
This trial has 7 study locations across Minnesota, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.